<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512452924</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512452924</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Topical Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of mitochondria in axonal degeneration and tissue repair in MS</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>van Horssen</surname><given-names>J</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512452924">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Witte</surname><given-names>ME</given-names></name>
<xref ref-type="aff" rid="aff1-1352458512452924">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ciccarelli</surname><given-names>O</given-names></name>
<xref ref-type="aff" rid="aff2-1352458512452924">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-1352458512452924"><label>1</label>Department of Molecular Cell Biology and Immunology, VU University Medical Center, The Netherlands</aff>
<aff id="aff2-1352458512452924"><label>2</label>Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, UK</aff>
<author-notes>
<fn fn-type="other">
<p>J.V.H. and M.E.W. contributed equally to this study.</p>
</fn>
<corresp id="corresp1-1352458512452924">J. van Horssen, Department of Molecular Cell Biology and Immunology, VU University Medical Center Amsterdam, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands. Email: <email>j.vanhorssen@vumc.nl</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2012</year>
</pub-date>
<volume>18</volume>
<issue>8</issue>
<fpage>1058</fpage>
<lpage>1067</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Axonal injury is a key feature of multiple sclerosis (MS) pathology and is currently seen as the main correlate for permanent clinical disability. Although little is known about the pathogenetic mechanisms that drive axonal damage and loss, there is accumulating evidence highlighting the central role of mitochondrial dysfunction in axonal degeneration and associated neurodegeneration. The aim of this topical review is to provide a concise overview on the involvement of mitochondrial dysfunction in axonal damage and destruction in MS. Hereto, we will discuss putative pathological mechanisms leading to mitochondrial dysfunction and recent imaging studies performed in vivo in patients with MS. Moreover, we will focus on molecular mechanisms and novel imaging studies that address the role of mitochondrial metabolism in tissue repair. Finally, we will briefly review therapeutic strategies aimed at improving mitochondrial metabolism and function under neuroinflammatory conditions.</p>
</abstract>
<kwd-group>
<kwd>Axonal injury</kwd>
<kwd>mitochondria</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>neurodegeneration</kwd>
<kwd>imaging</kwd>
<kwd>spectroscopy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1352458512452924">
<title>Axonal injury in multiple sclerosis</title>
<p>Multiple sclerosis (MS) is a chronic neuroinflammatory disorder of which the aetiology and pathogenesis are still enigmatic. Most MS patients experience an episodic course of the disease, with recurrent intervals of exacerbations followed by periods of remission. The relapsing–remitting phase is characterised by massive leukocyte infiltration and extensive microglial activation in the central nervous system (CNS). Histopathological analysis of MS brain tissue reveals the presence of focal white matter lesions distributed throughout the CNS. In the initial stages (acute), MS lesions are defined by primary demyelination with abundant inflammatory infiltrates that generally consist of lymphocytes, activated microglia and macrophages, which produce vast amounts of inflammatory mediators that break down the myelin sheet, with axonal conduction block as a consequence. As a bystander effect, inflammatory mediators also mediate transection of a subset of axons. These pathological processes are thought to underlie the acute clinical symptoms that characterise an MS relapse. More advanced stages of the disease, as seen in progressive MS, are mainly characterised by widespread cortical demyelination, neuronal damage and diffuse degenerative changes throughout the CNS. Taken together, evidence is accumulating that inflammation-induced axonal damage and demyelination occur in the initial stages of the disease, and over time degenerative processes take over, eventually leading to extensive axonal loss and brain atrophy.<sup><xref ref-type="bibr" rid="bibr1-1352458512452924">1</xref></sup></p>
<p>Axonal damage was already recognised by Charcot, and it is nowadays well understood that axonal damage and loss are key features of MS pathogenesis that correlate with permanent neurological deficits in MS patients.<sup><xref ref-type="bibr" rid="bibr2-1352458512452924">2</xref></sup> Although degenerating axons are mainly observed in active demyelinating lesions and associated with the number of infiltrated macrophages, activated microglia and CD8-positive T cells,<sup><xref ref-type="bibr" rid="bibr3-1352458512452924">3</xref></sup> axonal damage and loss are not restricted to early active lesions but also occur in more advanced stages of MS lesions.<sup><xref ref-type="bibr" rid="bibr4-1352458512452924">4</xref></sup> The invasion of blood-borne leukocytes in the early phase of the disease explains the efficacy of disease-modifying drugs in limiting relapses. However, these disease-modifying therapies do not halt the progression of the disease, and axonal injury and neuronal degeneration proceed.<sup><xref ref-type="bibr" rid="bibr5-1352458512452924">5</xref></sup> Therefore, current research focuses on understanding the pathogenic pathways that contribute to axonal injury in MS. In this respect, evidence is emerging that axonal pathology is tightly associated with mitochondrial alterations, and recent findings evidently demonstrate that mitochondrial dysfunction is not just a bystander phenomenon, but actively contributes to neurodegeneration and axonal injury.<sup><xref ref-type="bibr" rid="bibr6-1352458512452924">6</xref></sup></p>
</sec>
<sec id="section2-1352458512452924">
<title>Mitochondrial dysfunction in axonal damage: evidence from experimental and post-mortem studies</title>
<p>Pronounced mitochondrial defects have been reported in early and chronic white matter lesions.7–11 Mitochondrial density is increased in both axons and astrocytes in active demyelinating lesions and coincides with enhanced expression of mtHSP70, a well-characterised marker of mitochondrial stress.<sup><xref ref-type="bibr" rid="bibr9-1352458512452924">9</xref><xref ref-type="bibr" rid="bibr10-1352458512452924"/>–<xref ref-type="bibr" rid="bibr11-1352458512452924">11</xref></sup> Complex IV activity is significantly decreased in fulminant MS lesions and correlates with the number of activated microglia and infiltrated macrophages.<sup><xref ref-type="bibr" rid="bibr10-1352458512452924">10</xref></sup> In an experimental MS animal model, Nikić et al. demonstrated that intra-axonal mitochondrial defects, which already occur in the absence of overt demyelination, are an essential step towards axonal degeneration and local accumulation of invading macrophages. Interestingly, they showed that exogenous antioxidants were able to reduce mitochondrial pathology and thereby reduce axonal degeneration.<sup><xref ref-type="bibr" rid="bibr12-1352458512452924">12</xref></sup> In search of targets involved in excessive reactive oxygen species (ROS) ROS formation in MS, we performed microarray analysis on initial lesion areas and found a marked increase in NADPH oxidase-1 and -2 expression, which coincided with decreased mRNA levels of key mitochondrial proteins.<sup><xref ref-type="bibr" rid="bibr13-1352458512452924">13</xref></sup> Together, these findings indicate an important role for inflammation-derived ROS in axonal mitochondrial dysfunction in the initial stages of MS lesion formation.</p>
<p>In chronic MS lesions, and even in remyelinated lesions, mitochondrial alterations have been detected by biochemical and histochemical techniques.<sup><xref ref-type="bibr" rid="bibr9-1352458512452924">9</xref><xref ref-type="bibr" rid="bibr10-1352458512452924"/>–<xref ref-type="bibr" rid="bibr11-1352458512452924">11</xref>,<xref ref-type="bibr" rid="bibr14-1352458512452924">14</xref></sup> These reports revealed enhanced intra-axonal mitochondrial density and increased axonal complex IV activity in chronic MS lesions, which might be a compensatory mechanism for the observed complex I dysfunction. Likewise, increased mitochondrial density and complex IV activity have been observed in remyelinated axons.<sup><xref ref-type="bibr" rid="bibr14-1352458512452924">14</xref></sup> Axonal conduction, which is blocked by demyelination in highly inflammatory lesions, can be restored in chronic demyelinated axons by upregulation and reorganisation of voltage-gated Na<sup>+</sup> channels. Simultaneously, Na<sup>+</sup>/K<sup>+</sup> ATPase is upregulated to restore intra-axonal Na<sup>+</sup> concentration, resulting in an enhanced metabolic demand, which, in turn, leads to increased mitochondrial content and complex IV activity, which is seen in half of large chronically demyelinated axons (<xref ref-type="fig" rid="fig1-1352458512452924">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr10-1352458512452924">10</xref></sup> However, when the energy demand exceeds the ATP-producing capacity of mitochondria, demyelinated axons become chronically energy deficient, which is called ‘virtual hypoxia’;<sup><xref ref-type="bibr" rid="bibr15-1352458512452924">15</xref></sup> this will result in excessive sodium influx, which, in turn, drives the reverse action of the sodium-calcium exchanger, leading to calcium influx. This increased calcium influx, in combination with calcium released from mitochondria and via the glutamate-mediated pathway, mediates the subsequent axonal degeneration.<sup><xref ref-type="bibr" rid="bibr16-1352458512452924">16</xref></sup> In addition, dysfunctional mitochondria in chronic lesions are likely to generate vast amounts of ROS, leading to impaired mitochondrial function thereby creating a vicious cycle, which will inevitably damage the demyelinated axons.<sup><xref ref-type="bibr" rid="bibr17-1352458512452924">17</xref></sup> Thus, mitochondria are initially needed to preserve demyelinated axons, but in time set off a cascade of deleterious events leading to axonal injury and loss.<sup><xref ref-type="bibr" rid="bibr6-1352458512452924">6</xref>,<xref ref-type="bibr" rid="bibr18-1352458512452924">18</xref></sup></p>
<fig id="fig1-1352458512452924" position="float">
<label>Figure 1.</label>
<caption>
<p>Mitochondria are essential in restoring conduction in demyelinated axons. In normal, myelinated CNS axons conduction is saltatory, with de- and repolarisation taking place only at the nodes of Ranvier (<italic>upper panel</italic>). During depolarisation, voltage-gated sodium channels (Na<sub>v</sub>) are activated, thereby allowing Na<sup>+</sup> ions to flow into the axolemma. Repolarisation is an energy-dependent process in which axoplasmic Na<sup>+</sup> ions are exchanged for K<sup>+</sup> ions in the extracellular milieu by Na/K ATPase. In inflammatory MS lesions, the myelin sheet around axons is destroyed, thereby blocking saltatory conduction (<italic>middle panel</italic>). Conduction can be restored in demyelinated axons by upregulation and redistribution of Na<sub>v</sub> and Na/K ATPase. Consequently, intra-axonal mitochondrial content and complex IV activity is enhanced to meet the increasing ATP demand (<italic>lower panel</italic>).</p>
<p>CNS: central nervous system.</p>
</caption>
<graphic xlink:href="10.1177_1352458512452924-fig1.tif"/></fig>
<p>Mitochondrial alterations are not restricted to white matter MS lesions, and nowadays evidence is emerging that mitochondrial changes also occur in MS grey matter. Dutta and colleagues performed microarray analysis on myelinated cortex samples of progressive MS patients and revealed a marked decrease in the expression of genes involved in oxidative phosphorylation (OxPhos), which coincided with reduced neuronal activity of complex I and III.<sup><xref ref-type="bibr" rid="bibr7-1352458512452924">7</xref></sup> They postulated that these mitochondrial changes contributed to axonal degeneration and progressive neurological disability in MS patients.<sup><xref ref-type="bibr" rid="bibr7-1352458512452924">7</xref></sup> Recently, Mahad’s research group reported the presence of mtDNA deletions and respiratory-deficient neurons throughout the MS cortex.<sup><xref ref-type="bibr" rid="bibr8-1352458512452924">8</xref></sup> These findings point towards impaired oxidative metabolism in neurons in normal-appearing grey matter (NAGM) in MS patients, which subsequently leads to local energy deficits and increased mitochondrial ROS production, which in turn is a likely cause for the mtDNA deletions. Although the cause of mitochondrial changes in neurons in MS cortex is unknown, they will inevitably have an impact on axonal mitochondrial function, and thus on axonal survival under inflammatory or demyelinated conditions.</p>
</sec>
<sec id="section3-1352458512452924">
<title>Relationship between mitochondrial dysfunction and both acute and chronic neurological deficits: evidence from imaging</title>
<p>Acute neurological symptoms are thought to be due to conduction failure in demyelinated axons and axonal transection in acute inflammatory lesions. Irreversible (chronic) symptoms, instead, are considered to be related to the degeneration of axons and possibly to the gliotic response to tissue injury. In addition to the evidence discussed above that points to mitochondrial impairment as a key element in the pathogenesis of MS, insights into the mitochondrial function in vivo have been provided by imaging studies. In particular, proton and phosphorus (<sup>1</sup>H and <sup>31</sup>P) magnetic resonance spectroscopy (<sup>1</sup>H-MRS and <sup>31</sup>P-MRS) allows detection of changes in the concentration of several proton- and phosphorus-containing compounds, which have high specificity for different pathological processes;<sup><xref ref-type="bibr" rid="bibr19-1352458512452924">19</xref></sup> some of these metabolites may reflect ‘indirectly’ or ‘directly’ the status of mitochondrial metabolism within neurons or in any other cell type (<xref ref-type="table" rid="table1-1352458512452924">Table 1</xref>).</p>
<table-wrap id="table1-1352458512452924" position="float">
<label>Table 1.</label>
<caption>
<p>Pathological specificity of imaging markers for mitochondrial metabolism and their clinical relevance.</p>
</caption>
<graphic alternate-form-of="table1-1352458512452924" xlink:href="10.1177_1352458512452924-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Imaging marker</th>
<th align="left">Specificity for neurons</th>
<th align="left">Specificity for mitochondrial metabolism</th>
<th align="left">Specificity for axonal loss</th>
<th align="left">Correlation with clinical disability</th>
<th align="left">Use in clinical trials</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="6"><bold><sup>1</sup>H-MRS</bold></td>
</tr>
<tr>
<td>NAA</td>
<td>High (in adult brain)</td>
<td>Good, depending on its synthesis and role in neuronal mitochondria.</td>
<td>Good</td>
<td>Good</td>
<td>Reported</td>
</tr>
<tr>
<td>Glutathione</td>
<td>Low</td>
<td>Theoretically good, but depending on the extent of the link between oxidative stress and mitochondrial dysfunction.</td>
<td>Low</td>
<td>Unknown</td>
<td>Not done</td>
</tr>
<tr>
<td>Lactate</td>
<td>Low</td>
<td>Good, but indirect, reflecting non-mitochondrial anaerobic metabolism which increases if mitochondrial function is impaired.</td>
<td>Low</td>
<td>Unknown</td>
<td>Not done</td>
</tr>
<tr>
<td colspan="6"><bold><sup>31</sup>P-MRS</bold></td>
</tr>
<tr>
<td>Phosphorus metabolites</td>
<td>Low</td>
<td>High and direct.</td>
<td>Low</td>
<td>Unknown</td>
<td>Not done</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512452924">
<p><sup>1</sup>H-MRS: proton magnetic resonance spectroscopy; <sup>31</sup>P-MRS: phosphorus magnetic resonance spectroscopy.</p></fn>
</table-wrap-foot></table-wrap>
<p>N-acetyl-aspartate (NAA) is in a key position to be a <sup>1</sup>H-MRS marker of neuronal health and density and is present at very high concentration in the brain.<sup><xref ref-type="bibr" rid="bibr20-1352458512452924">20</xref></sup> Although the metabolic and neurochemical functions of NAA are not fully known, it is thought to be indirectly linked with ATP metabolism. NAA is synthesised in neuronal mitochondria and plays a role in enhancing mitochondrial energy production.<sup><xref ref-type="bibr" rid="bibr20-1352458512452924">20</xref></sup> Therefore, reduced NAA concentration reflects impaired neuronal mitochondrial metabolism<sup><xref ref-type="bibr" rid="bibr21-1352458512452924">21</xref></sup> in addition to neuronal cell loss;<sup><xref ref-type="bibr" rid="bibr22-1352458512452924">22</xref></sup> this indicates that the specificity of NAA for neuronal mitochondrial dysfunction is limited, but unique. Bearing in mind this important aspect, a significant decrease in the concentration of NAA (including NAA-glutamate) in the lesional and normal-appearing white matter and in the NAGM of the brain of patients with MS when compared to healthy subjects has been often reported, with mean (SD) decreases of about 20% in the lesions and 7% in the normal-appearing brain tissue<sup><xref ref-type="bibr" rid="bibr23-1352458512452924">23</xref></sup> (<xref ref-type="fig" rid="fig2-1352458512452924">Figure 2</xref>). A decrease in NAA levels has also been described in the spinal cord of MS patients when compared to controls; this decrease varied between 39% at the level of an acute lesion at the onset of a spinal cord relapse<sup><xref ref-type="bibr" rid="bibr24-1352458512452924">24</xref></sup> and 21% (as ratio of NAA/total choline) in chronic spinal cord lesions.<sup><xref ref-type="bibr" rid="bibr25-1352458512452924">25</xref></sup> Furthermore, a significant reduction in NAA concentration was found in all types of MS,<sup><xref ref-type="bibr" rid="bibr23-1352458512452924">23</xref></sup> especially in the progressive forms<sup><xref ref-type="bibr" rid="bibr26-1352458512452924">26</xref>,<xref ref-type="bibr" rid="bibr27-1352458512452924">27</xref></sup> and even in patients with clinically isolated syndrome.<sup><xref ref-type="bibr" rid="bibr28-1352458512452924">28</xref></sup> With regard to the clinical relevance of NAA, several MRS studies have described an association between reduced NAA and increased disability, as measured by the Expanded Disability Status Scale (EDSS) during an acute relapse<sup><xref ref-type="bibr" rid="bibr24-1352458512452924">24</xref>,<xref ref-type="bibr" rid="bibr29-1352458512452924">29</xref></sup> and in the chronic stage of the disease.<sup><xref ref-type="bibr" rid="bibr22-1352458512452924">22</xref></sup> Additionally, NAA levels (or NAA/creatine ratio) correlate with fatigue<sup><xref ref-type="bibr" rid="bibr30-1352458512452924">30</xref></sup> and cognitive function<sup><xref ref-type="bibr" rid="bibr31-1352458512452924">31</xref>,<xref ref-type="bibr" rid="bibr32-1352458512452924">32</xref></sup> and predict disease evolution in patients with clinically isolated syndrome.<sup><xref ref-type="bibr" rid="bibr33-1352458512452924">33</xref>,<xref ref-type="bibr" rid="bibr34-1352458512452924">34</xref></sup></p>
<fig id="fig2-1352458512452924" position="float">
<label>Figure 2.</label>
<caption>
<p>Two representative <sup>1</sup>H-MRS spectra on the right with the corresponding Chemical Shift Imaging grid on the left. On the top, spectrum obtained from a spectroscopic voxel localised on the normal-appearing white matter of a 42-year-old female patient with secondary progressive MS, showing reduced NAA peak compared to the spectrum on the bottom, which is obtained from a voxel localised on the normal white matter of a 38-year-old healthy control. <italic>Courtesy of Dr David Pailing (UCL Institute of Neurology)</italic>.</p>
<p><sup>1</sup>H-MRS: proton magnetic resonance spectroscopy; NAA: N-acetyl-aspartate; MS: multiple sclerosis.</p>
</caption>
<graphic xlink:href="10.1177_1352458512452924-fig2.tif"/></fig>
<p>As discussed above, axonal mitochondria are damaged by the vast amount of ROS produced by macrophages and activated microglia. Glutathione is a potent antioxidant that protects cells against the deleterious effects of ROS. Since glutathione is consumed in this protective task, a reduction in glutathione levels is expected to reflect oxidative stress<sup><xref ref-type="bibr" rid="bibr35-1352458512452924">35</xref></sup> and, therefore, subsequent impaired mitochondrial function. The levels of glutathione were found to be reduced in patients with MS when compared to healthy subjects in the frontal regions of the brain at 3 T<sup><xref ref-type="bibr" rid="bibr36-1352458512452924">36</xref></sup> and in the grey matter and in an MS lesion at 7 T,<sup><xref ref-type="bibr" rid="bibr37-1352458512452924">37</xref></sup> suggesting the presence of underlying oxidative damage in tissue, especially to mitochondria.</p>
<p>Another metabolite measured with <sup>1</sup>H-MRS which provides a window for the study of mitochondrial dysfunction is lactate. In the presence of impaired mitochondrial oxidative metabolism, there is a shift from aerobic to anaerobic metabolism, and, therefore, the production of lactate increases.<sup><xref ref-type="bibr" rid="bibr38-1352458512452924">38</xref></sup> Increased lactate levels are present within the acute (enhancing) lesions, tend to decrease progressively over time, but may remain elevated for several weeks,<sup><xref ref-type="bibr" rid="bibr39-1352458512452924">39</xref>,<xref ref-type="bibr" rid="bibr40-1352458512452924">40</xref></sup> suggesting an increased glycolytic activity by macrophages and reactive glia, even when the blood-brain barrier is repaired (i.e. no gadolinium-enhancing lesion is seen).</p>
<p>A more direct measure of mitochondrial function is provided by <sup>31</sup>P-MRS. The major <sup>31</sup>P-MRS peaks include high-energy phosphates, such as alpha, beta and gamma nucleotide triphosphates (reflecting ATP), phosphocreatine (PCr: an indicator of oxidative metabolism) and inorganic phosphate (Pi) (<xref ref-type="fig" rid="fig3-1352458512452924">Figure 3</xref>). Therefore, the rate of mitochondrial metabolism and, in particular, of oxidative phosphorylation, is reflected by the ratio of Pi to PCr: reduced concentration of PCr (which transfers a phosphate group to ADP), together with increased Pi levels, in the presence of unchanged ATP levels. These metabolic changes suggest decreased intracellular energy metabolism, without specificity for cell type and independently from the cause of reduced energy metabolism, which may include decreased oxygen availability or blood flow, increased energy demand and impaired mitochondrial function. Both reduced and increased PCr ratios have been found within MS lesions and/or white matter, as recently summarised by Hattingen and colleagues<sup><xref ref-type="bibr" rid="bibr41-1352458512452924">41</xref></sup> in agreement with the hypothesis that changes in energy metabolism may occur towards either reduced mitochondrial metabolism or increased energy production (in excess of demand). However, comparison between studies is challenging because of differences in patient cohorts and imaging protocols. A recent paper that combined <sup>1</sup>H-MRS with <sup>31</sup>P-MRS demonstrated that the ratio between PCr and Cr in the centrum semiovale did not change in MS when compared with controls (the increase in PCr was in fact proportional to the increase in total Cr);<sup><xref ref-type="bibr" rid="bibr41-1352458512452924">41</xref></sup> this finding suggests an overall, non-significant change in the cellular energy state of the underlying tissue.</p>
<fig id="fig3-1352458512452924" position="float">
<label>Figure 3.</label>
<caption>
<p>Representative <sup>31</sup>P-MRS spectrum with (<italic>bottom</italic>) and without (<italic>middle</italic>) baseline, correction obtained from a spectroscopic volume localised in the occipital cortex of a healthy subject. <italic>Courtesy of Stephanie Bowen and Bhavana Solanky (UCL Institute of Neurology)</italic>.</p>
<p><sup>31</sup>P-MRS: phosphorus magnetic resonance spectroscopy.</p>
</caption>
<graphic xlink:href="10.1177_1352458512452924-fig3.tif"/></fig>
<p>In conclusion, despite the diversity of technical approaches and protocols, abnormalities consistent with mitochondrial dysfunction have been directly (or indirectly) detected in the brain and spinal cord in the acute and chronic phases of MS, although high specificity for neuronal cells is rarely achieved. Future studies will focus on combining <sup>1</sup>H-MRS with <sup>31</sup>P-MRS to provide a more specific approach to assess mitochondrial function and energy demand in order to develop biomarkers for evaluating therapeutic responses.</p>
</sec>
<sec id="section4-1352458512452924">
<title>Link between mitochondrial metabolism and tissue repair: evidence from post-mortem and imaging</title>
<p>Axonal injury and neuronal damage are considered to be responsible for permanent, non-remitting, clinical deficits. Concomitant with the axonal degeneration that follows an acute inflammatory event, repair mechanisms spontaneously take place and lead to clinical improvement. For example, about 65% of MS patients with an acute relapse caused by a new cervical cord lesion improved clinically during a six-month follow-up study.<sup><xref ref-type="bibr" rid="bibr42-1352458512452924">42</xref></sup> Mechanisms of repair include resolution of inflammation, remyelination and possibly cortical adaptation. The increases in mitochondrial mass and complex IV activity within half of large chronically demyelinated axons<sup><xref ref-type="bibr" rid="bibr44-1352458512452924">44</xref></sup> may reflect a compensatory reaction to the increased energy demand (<xref ref-type="fig" rid="fig1-1352458512452924">Figure 1</xref>). This post-mortem evidence is in agreement with the findings of increased mitochondrial number and activity in the white matter tracts of shiverer mutant mice, which lack CNS myelin.<sup><xref ref-type="bibr" rid="bibr45-1352458512452924">45</xref></sup> In this model, intra-axonal mitochondrial changes may be a direct response to the enhanced energy requirement in axons lacking myelin in a non-inflammatory environment.</p>
<p>A recent study carried out in patients with relapsing–remitting MS followed-up after an acute spinal cord relapse reported a reduction in NAA levels after one month from onset, and a sustained increase in NAA concentration from one to six months<sup><xref ref-type="bibr" rid="bibr42-1352458512452924">42</xref></sup> (<xref ref-type="fig" rid="fig4-1352458512452924">Figure 4</xref>). This increase in NAA levels is significant when correcting for the concomitant development of spinal cord atrophy, which occurs during the same follow-up and suggests ongoing axonal loss. As discussed before, NAA concentration reflects both axonal integrity and axonal mitochondrial metabolism; therefore, an increase in NAA levels, occurring in parallel with atrophy development, may be driven by increased axonal mitochondrial metabolism. The contribution of remyelination to these NAA changes is thought to be negligible.<sup><xref ref-type="bibr" rid="bibr20-1352458512452924">20</xref></sup> Previous brain studies reported a similar reversible decrease in NAA concentration after an acute lesion.<sup><xref ref-type="bibr" rid="bibr46-1352458512452924">46</xref><xref ref-type="bibr" rid="bibr47-1352458512452924"/>–<xref ref-type="bibr" rid="bibr48-1352458512452924">48</xref></sup> An interesting clinical observation is that the observed increase in NAA over time correlates with clinical recovery, and is less evident in patients with longer disease duration.<sup><xref ref-type="bibr" rid="bibr42-1352458512452924">42</xref></sup> Although technical limitations are present in this type of MRS studies, these findings suggest that the increased energy production, which occurs in response to acute demyelination, may have an impact on clinical recovery. In addition, the repair mechanisms involving mitochondrial metabolism, and reflected by the increase in NAA levels, may become less efficient over time.</p>
<fig id="fig4-1352458512452924" position="float">
<label>Figure 4.</label>
<caption>
<p><sup>1</sup>H-MRS spectroscopic volumes and spectra from the same relapsing–remitting patient at onset of a spinal cord relapse (<italic>left</italic>) due to a lesion between C1 and C3 and after six months (<italic>right</italic>). The top row shows the MRS volume positioned between C1 and C3 on sagittal images at baseline (<italic>left</italic>) and follow-up (<italic>right</italic>). The concentration of NAA was 2.53 mM at study entry (<italic>left</italic>), and 2.24 mM after six months (<italic>right</italic>). The EDSS of this patient significantly improved by one point between baseline and six months.</p>
<p><sup>1</sup>H-MRS: proton magnetic resonance spectroscopy; NAA: N-acetyl-aspartate; EDSS: Expanded Disability Status Scale.</p>
</caption>
<graphic xlink:href="10.1177_1352458512452924-fig4.tif"/></fig>
<p>After six months from onset of a spinal cord relapse, patients who present a higher ‘metabolic’ component of the NAA are less likely to have greater disability and show better walking ability than those with a lower ‘metabolic’ component.<sup><xref ref-type="bibr" rid="bibr49-1352458512452924">49</xref></sup> This ‘metabolic’ component has been estimated statistically combining NAA with other imaging measures of axonal loss and degeneration. This novel approach allows an estimate of the NAA changes which cannot be explained by the imaging structural measures, and therefore likely reflects mitochondrial metabolism. Future studies will concentrate on extracting the metabolic component of NAA using more complex statistical models, and validating this novel method with experimental animal models.</p>
</sec>
<sec id="section5-1352458512452924">
<title>Therapeutic strategies aimed at restoring mitochondrial function</title>
<p>The studies reviewed in this paper demonstrate that mitochondrial metabolism is essential in maintaining axonal integrity and survival during the initial and progressive stages of MS. As such, mitochondria as well as pathogenetic mechanisms that drive mitochondrial dysfunction, such as oxidative stress, represent attractive therapeutic targets.<sup><xref ref-type="bibr" rid="bibr50-1352458512452924">50</xref></sup> There are several options to limit oxidative stress and associated mitochondrial dysfunction: 1) pharmacological inhibitors of enzymes involved in free radical formation, e.g. NADPH oxidase inhibitors; 2) activation of pathways inducing the production of endogenous antioxidant enzymes, e.g. fumaric acid esters or 3) mitochondria-targeted antioxidants, such as MitoQ.<sup><xref ref-type="bibr" rid="bibr51-1352458512452924">51</xref></sup> Although in vitro studies have clearly demonstrated the beneficial effects of these approaches, future research is needed to explore their efficacy in a human setting. Importantly, some compounds, including the Nrf2 activator BG12 and the mitochondria-targeted antioxidant MitoQ, have been shown to exert protective effects in clinical trials.<sup><xref ref-type="bibr" rid="bibr52-1352458512452924">52</xref>,<xref ref-type="bibr" rid="bibr53-1352458512452924">53</xref></sup> <sup>1</sup>H-MRS and <sup>31</sup>P-MRS, in combination with structural imaging techniques, should be further explored in order to obtain in vivo information on mitochondrial energy metabolism, and introduce new imaging outcomes for treatment trials with agents that protect and modulate mitochondrial function.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding statement</label>
<p>This review is based on studies funded by the Dutch MS Research Foundation (09-686 MS and 09-358d to JvH) and the Wellcome Trust and MS Society for Great Britain and Northern Ireland (O.C).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>The authors declare that they have no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512452924">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lassmann</surname><given-names>H</given-names></name>
<name><surname>van Horssen</surname><given-names>J</given-names></name>
</person-group>. <article-title>The molecular basis of neurodegeneration in multiple sclerosis</article-title>. <source>FEBS Lett</source> <year>2011</year>; <volume>585</volume>: <fpage>3715</fpage>–<lpage>3723</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512452924">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stadelmann</surname><given-names>C</given-names></name>
</person-group>. <article-title>Multiple sclerosis as a neurodegenerative disease: pathology, mechanisms and therapeutic implications</article-title>. <source>Curr Opin Neurol</source> <year>2011</year>; <volume>24</volume>: <fpage>224</fpage>–<lpage>229</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512452924">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bitsch</surname><given-names>A</given-names></name>
<name><surname>Schuchardt</surname><given-names>J</given-names></name>
<name><surname>Bunkowski</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation</article-title>. <source>Brain</source> <year>2000</year>; <volume>123</volume>: <fpage>1174</fpage>–<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512452924">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kornek</surname><given-names>B</given-names></name>
<name><surname>Storch</surname><given-names>MK</given-names></name>
<name><surname>Weissert</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions</article-title>. <source>Am J Pathol</source> <year>2000</year>; <volume>157</volume>: <fpage>267</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512452924">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filippini</surname><given-names>G</given-names></name>
<name><surname>Munari</surname><given-names>L</given-names></name>
<name><surname>Incorvaia</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Interferons in relapsing remitting multiple sclerosis: a systematic review</article-title>. <source>Lancet</source> <year>2003</year>; <volume>361</volume>: <fpage>545</fpage>–<lpage>552</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512452924">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witte</surname><given-names>ME</given-names></name>
<name><surname>Geurts</surname><given-names>JJ</given-names></name>
<name><surname>de Vries</surname><given-names>HE</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondrial dysfunction: a potential link between neuroinflammation and neurodegeneration?</article-title> <source>Mitochondrion</source>. <year>2010</year>; <volume>5</volume>: <fpage>411</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512452924">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dutta</surname><given-names>R</given-names></name>
<name><surname>McDonough</surname><given-names>J</given-names></name>
<name><surname>Yin</surname><given-names>X</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients</article-title>. <source>Ann Neurol</source> <year>2006</year>; <volume>59</volume>: <fpage>478</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512452924">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Campbell</surname><given-names>GR</given-names></name>
<name><surname>Ziabreva</surname><given-names>I</given-names></name>
<name><surname>Reeve</surname><given-names>AK</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>481</fpage>–<lpage>492</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512452924">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Witte</surname><given-names>ME</given-names></name>
<name><surname>Bo</surname><given-names>L</given-names></name>
<name><surname>Rodenburg</surname><given-names>RJ</given-names></name>
<etal/>
</person-group>. <article-title>Enhanced number and activity of mitochondria in multiple sclerosis lesions</article-title>. <source>J Pathol</source> <year>2009</year>; <volume>2</volume>: <fpage>193</fpage>–<lpage>204</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512452924">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mahad</surname><given-names>D</given-names></name>
<name><surname>Ziabreva</surname><given-names>I</given-names></name>
<name><surname>Lassmann</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondrial defects in acute multiple sclerosis lesions</article-title>. <source>Brain</source> <year>2008</year>; <volume>131</volume>: <fpage>1722</fpage>–<lpage>1735</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512452924">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>F</given-names></name>
<name><surname>Selak</surname><given-names>M</given-names></name>
<name><surname>O’Connor</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis</article-title>. <source>J Neurol Sci</source> <year>2000</year>; <volume>177</volume>: <fpage>95</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512452924">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nikić</surname><given-names>I</given-names></name>
<name><surname>Merkler</surname><given-names>D</given-names></name>
<name><surname>Sorbara</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis</article-title>. <source>Nat Med</source> <year>2011</year>; <volume>17</volume>: <fpage>495</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512452924">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fischer</surname><given-names>MT</given-names></name>
<name><surname>Sharma</surname><given-names>R</given-names></name>
<name><surname>Lim</surname><given-names>JL</given-names></name>
<etal/>
</person-group>. <article-title>NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury</article-title>. <source>Brain</source> <year>2012</year>; <volume>135</volume>: <fpage>886</fpage>–<lpage>899</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512452924">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zambonin</surname><given-names>JL</given-names></name>
<name><surname>Zhao</surname><given-names>C</given-names></name>
<name><surname>Ohno</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis</article-title>. <source>Brain</source> <year>2011</year>; <volume>134</volume>: <fpage>1901</fpage>–<lpage>1913</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512452924">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trapp</surname><given-names>BD</given-names></name>
<name><surname>Stys</surname><given-names>PK</given-names></name>
</person-group>. <article-title>Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis</article-title>. <source>Lancet Neurol</source>. <year>2009</year>; <volume>8</volume>: <fpage>280</fpage>–<lpage>291</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512452924">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis</article-title>. <source>Trends Mol Med</source> <year>2006</year>; <volume>12</volume>: <fpage>192</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512452924">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>KJ</given-names></name>
</person-group>. <article-title>Newly lesioned tissue in multiple sclerosis—a role for oxidative damage?</article-title> <source>Brain</source> <year>2011</year>; <volume>134</volume> (<issue>Pt 7</issue>): <fpage>1877</fpage>–<lpage>1881</lpage>. <comment>Epub 15 June 2011</comment>.</citation>
</ref>
<ref id="bibr18-1352458512452924">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mahad</surname><given-names>D</given-names></name>
<name><surname>Lassmann</surname><given-names>H</given-names></name>
<name><surname>Turnbull</surname><given-names>D</given-names></name>
</person-group>. <article-title>Review: mitochondria and disease progression in multiple sclerosis</article-title>. <source>Neuropathol Appl Neurobiol</source> <year>2008</year>; <volume>34</volume>: <fpage>577</fpage>–<lpage>589</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512452924">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sajja</surname><given-names>BR</given-names></name>
<name><surname>Wolinsky</surname><given-names>JS</given-names></name>
<name><surname>Narayana</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Proton magnetic resonance spectroscopy in multiple sclerosis</article-title>. <source>Neuroimaging Clin N Am</source> <year>2009</year>; <volume>19</volume>: <fpage>45</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512452924">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moffett</surname><given-names>JR</given-names></name>
<name><surname>Ross</surname><given-names>B</given-names></name>
<name><surname>Arun</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology</article-title>. <source>Prog Neurobiol</source> <year>2007</year>; <volume>81</volume>: <fpage>89</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512452924">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bates</surname><given-names>TE</given-names></name>
<name><surname>Strangward</surname><given-names>M</given-names></name>
<name><surname>Keelan</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo</article-title>. <source>Neuroreport</source> <year>1996</year>; <volume>7</volume>: <fpage>1397</fpage>–<lpage>1400</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512452924">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bjartmar</surname><given-names>C</given-names></name>
<name><surname>Kidd</surname><given-names>G</given-names></name>
<name><surname>Mörk</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients</article-title>. <source>Ann Neurol</source> <year>2000</year>; <volume>48</volume>: <fpage>893</fpage>–<lpage>901</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512452924">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Caramanos</surname><given-names>Z</given-names></name>
<name><surname>Narayanan</surname><given-names>S</given-names></name>
<name><surname>Arnold</surname><given-names>DL</given-names></name>
</person-group>. <article-title>1H-MRS quantification of tNA and tCr in patients with multiple sclerosis: a meta-analytic review</article-title>. <source>Brain</source> <year>2005</year>; <volume>128</volume> (<issue>Pt 11</issue>): <fpage>2483</fpage>–<lpage>2506</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512452924">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciccarelli</surname><given-names>O</given-names></name>
<name><surname>Wheeler-Kingshott</surname><given-names>CA</given-names></name>
<name><surname>McLean</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. <article-title>Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis</article-title>. <source>Brain</source> <year>2007</year>; <volume>130</volume> (<issue>Pt 8</issue>): <fpage>2220</fpage>–<lpage>2231</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512452924">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marliani</surname><given-names>AF</given-names></name>
<name><surname>Clementi</surname><given-names>V</given-names></name>
<name><surname>Albini Riccioli</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Quantitative cervical spinal cord 3T proton MR spectroscopy in multiple sclerosis</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2010</year>; <volume>31</volume>: <fpage>180</fpage>–<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512452924">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hannoun</surname><given-names>S</given-names></name>
<name><surname>Bagory</surname><given-names>M</given-names></name>
<name><surname>Durand-Dubief</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Correlation of diffusion and metabolic alterations in different clinical forms of multiple sclerosis</article-title>. <source>PLoS One</source> <year>2012</year>; <volume>7</volume>: <fpage>e32525</fpage>.</citation>
</ref>
<ref id="bibr27-1352458512452924">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aboul-Enein</surname><given-names>F</given-names></name>
<name><surname>Krssák</surname><given-names>M</given-names></name>
<name><surname>Höftberger</surname><given-names>R</given-names></name>
<etal/>
</person-group>. <article-title>Reduced NAA-levels in the NAWM of patients with MS is a feature of progression. A study with quantitative magnetic resonance spectroscopy at 3 Tesla</article-title>. <source>PLoS One</source> <year>2010</year>; <volume>5</volume>: <fpage>e11625</fpage>.</citation>
</ref>
<ref id="bibr28-1352458512452924">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wattjes</surname><given-names>MP</given-names></name>
<name><surname>Harzheim</surname><given-names>M</given-names></name>
<name><surname>Lutterbey</surname><given-names>GG</given-names></name>
<etal/>
</person-group>. <article-title>Axonal damage but no increased glial cell activity in the normal-appearing white matter of patients with clinically isolated syndromes suggestive of multiple sclerosis using high-field magnetic resonance spectroscopy</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2007</year>; <volume>28</volume>: <fpage>1517</fpage>–<lpage>1522</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512452924">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Stefano</surname><given-names>N</given-names></name>
<name><surname>Matthews</surname><given-names>PM</given-names></name>
<name><surname>Fu</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Axonal damage correlates with disability in patients with relapsing–remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study</article-title>. <source>Brain</source> <year>1998</year>; <volume>121</volume> (<issue>Pt 8</issue>): <fpage>1469</fpage>–<lpage>1477</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512452924">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tartaglia</surname><given-names>MC</given-names></name>
<name><surname>Narayanan</surname><given-names>S</given-names></name>
<name><surname>Francis</surname><given-names>SJ</given-names></name>
<etal/>
</person-group>. <article-title>The relationship between diffuse axonal damage and fatigue in multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2004</year>; <volume>61</volume>: <fpage>201</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr31-1352458512452924">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gadea</surname><given-names>M</given-names></name>
<name><surname>Martinez-Bisbal</surname><given-names>MC</given-names></name>
<name><surname>Marti-Bonmati</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing–remitting multiple sclerosis</article-title>. <source>Brain</source> <year>2004</year>; <volume>127</volume> (<issue>Pt 1</issue>): <fpage>89</fpage>–<lpage>98</lpage>.</citation>
</ref>
<ref id="bibr32-1352458512452924">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mathiesen</surname><given-names>HK</given-names></name>
<name><surname>Jonsson</surname><given-names>A</given-names></name>
<name><surname>Tscherning</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis</article-title>. <source>Arch Neurol</source> <year>2006</year>; <volume>63</volume>: <fpage>533</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr33-1352458512452924">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sbardella</surname><given-names>E</given-names></name>
<name><surname>Tomassini</surname><given-names>V</given-names></name>
<name><surname>Stromillo</surname><given-names>ML</given-names></name>
<etal/>
</person-group>. <article-title>Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>1432</fpage>–<lpage>1440</lpage>.</citation>
</ref>
<ref id="bibr34-1352458512452924">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wattjes</surname><given-names>MP</given-names></name>
<name><surname>Harzheim</surname><given-names>M</given-names></name>
<name><surname>Lutterbey</surname><given-names>GG</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis</article-title>. <source>Neuroradiology</source> <year>2008</year>; <volume>50</volume>: <fpage>123</fpage>–<lpage>129</lpage>.</citation>
</ref>
<ref id="bibr35-1352458512452924">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bains</surname><given-names>JS</given-names></name>
<name><surname>Shaw</surname><given-names>CA</given-names></name>
</person-group>. <article-title>Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death</article-title>. <source>Brain Res Brain Res Rev</source> <year>1997</year>; <volume>25</volume>: <fpage>335</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr36-1352458512452924">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Choi</surname><given-names>IY</given-names></name>
<name><surname>Lee</surname><given-names>SP</given-names></name>
<name><surname>Denney</surname><given-names>DR</given-names></name>
<etal/>
</person-group>. <article-title>Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>289</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr37-1352458512452924">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Srinivasan</surname><given-names>R</given-names></name>
<name><surname>Ratiney</surname><given-names>H</given-names></name>
<name><surname>Hammond-Rosenbluth</surname><given-names>KE</given-names></name>
<etal/>
</person-group>. <article-title>MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis</article-title>. <source>Magn Reson Imaging</source> <year>2010</year>; <volume>28</volume>: <fpage>163</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr38-1352458512452924">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saneto</surname><given-names>RP</given-names></name>
<name><surname>Friedman</surname><given-names>SD</given-names></name>
<name><surname>Shaw</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Neuroimaging of mitochondrial disease</article-title>. <source>Mitochondrion</source> <year>2008</year>; <volume>8</volume>: <fpage>396</fpage>–<lpage>413</lpage>.</citation>
</ref>
<ref id="bibr39-1352458512452924">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zaaraoui</surname><given-names>W</given-names></name>
<name><surname>Rico</surname><given-names>A</given-names></name>
<name><surname>Audoin</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Unfolding the long-term pathophysiological processes following an acute inflammatory demyelinating lesion of multiple sclerosis</article-title>. <source>Magn Reson Imaging</source> <year>2010</year>; <volume>28</volume>: <fpage>477</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr40-1352458512452924">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Paling</surname><given-names>D</given-names></name>
<name><surname>Golay</surname><given-names>X</given-names></name>
<name><surname>Wheeler-Kingshott</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Energy failure in multiple sclerosis and its investigation using MR techniques</article-title>. <source>J Neurol</source> <year>2011</year>; <volume>258</volume>: <fpage>2113</fpage>–<lpage>2127</lpage>.</citation>
</ref>
<ref id="bibr41-1352458512452924">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hattingen</surname><given-names>E</given-names></name>
<name><surname>Magerkurth</surname><given-names>J</given-names></name>
<name><surname>Pilatus</surname><given-names>U</given-names></name>
<etal/>
</person-group>. <article-title>Combined (1)H and (31)P spectroscopy provides new insights into the pathobiochemistry of brain damage in multiple sclerosis</article-title>. <source>NMR Biomed</source> <year>2011</year>; <volume>24</volume>: <fpage>536</fpage>–<lpage>546</lpage>.</citation>
</ref>
<ref id="bibr42-1352458512452924">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciccarelli</surname><given-names>O</given-names></name>
<name><surname>Altmann</surname><given-names>DR</given-names></name>
<name><surname>McLean</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. <article-title>Spinal cord repair in MS: does mitochondrial metabolism play a role?</article-title> <source>Neurology</source> <year>2010</year>; <volume>74</volume>: <fpage>721</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr43-1352458512452924">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waxman</surname><given-names>SG</given-names></name>
</person-group>. <article-title>Demyelinating diseases—new pathological insights, new therapeutic targets</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>338</volume>: <fpage>323</fpage>–<lpage>325</lpage>.</citation>
</ref>
<ref id="bibr44-1352458512452924">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mahad</surname><given-names>DJ</given-names></name>
<name><surname>Ziabreva</surname><given-names>I</given-names></name>
<name><surname>Campbell</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondrial changes within axons in multiple sclerosis</article-title>. <source>Brain</source> <year>2009</year>; <volume>132</volume> (<issue>Pt 5</issue>): <fpage>1161</fpage>–<lpage>1174</lpage>.</citation>
</ref>
<ref id="bibr45-1352458512452924">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andrews</surname><given-names>H</given-names></name>
<name><surname>White</surname><given-names>K</given-names></name>
<name><surname>Thomson</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Increased axonal mitochondrial activity as an adaptation to myelin deficiency in the Shiverer mouse</article-title>. <source>J Neurosci Res</source> <year>2006</year>; <volume>83</volume>: <fpage>1533</fpage>–<lpage>1539</lpage>.</citation>
</ref>
<ref id="bibr46-1352458512452924">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Stefano</surname><given-names>N</given-names></name>
<name><surname>Matthews</surname><given-names>PM</given-names></name>
<name><surname>Arnold</surname><given-names>DL</given-names></name>
</person-group>. <article-title>Reversible decreases in N-acetylaspartate after acute brain injury</article-title>. <source>Magn Reson Med</source> <year>1995</year>; <volume>34</volume>: <fpage>721</fpage>–<lpage>727</lpage>.</citation>
</ref>
<ref id="bibr47-1352458512452924">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davie</surname><given-names>CA</given-names></name>
<name><surname>Hawkins</surname><given-names>CP</given-names></name>
<name><surname>Barker</surname><given-names>GJ</given-names></name>
<etal/>
</person-group>. <article-title>Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions</article-title>. <source>Brain</source> <year>1994</year>; <volume>117</volume> (<issue>Pt 1</issue>): <fpage>49</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr48-1352458512452924">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mader</surname><given-names>I</given-names></name>
<name><surname>Roser</surname><given-names>W</given-names></name>
<name><surname>Kappos</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study</article-title>. <source>AJNR Am J Neuroradiol</source> <year>2000</year>; <volume>21</volume>: <fpage>1220</fpage>–<lpage>1227</lpage>.</citation>
</ref>
<ref id="bibr49-1352458512452924">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ciccarelli</surname><given-names>O</given-names></name>
<name><surname>Toosy</surname><given-names>AT</given-names></name>
<name><surname>De Stefano</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Assessing neuronal metabolism in vivo by modeling imaging measures</article-title>. <source>J Neurosci</source> <year>2010</year>; <volume>30</volume>: <fpage>15030</fpage>–<lpage>15033</lpage>.</citation>
</ref>
<ref id="bibr50-1352458512452924">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Horssen</surname><given-names>J</given-names></name>
<name><surname>Witte</surname><given-names>ME</given-names></name>
<name><surname>Schreibelt</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Radical changes in multiple sclerosis pathogenesis</article-title>. <source>Biochim Biophys Acta</source> <year>2011</year>; <volume>2</volume>: <fpage>141</fpage>–<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr51-1352458512452924">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Smith</surname><given-names>RA</given-names></name>
<name><surname>Adlam</surname><given-names>VJ</given-names></name>
<name><surname>Blaikie</surname><given-names>FH</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondria-targeted antioxidants in the treatment of disease</article-title>. <source>Ann N Y Acad Sci</source> <year>2008</year>; <volume>1147</volume>: <fpage>105</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr52-1352458512452924">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kappos</surname><given-names>L</given-names></name>
<name><surname>Gold</surname><given-names>R</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<etal/>
</person-group>. <article-title>Efficacy and safety of oral fumarate in patients with relapsing–remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study</article-title>. <source>Lancet</source> <year>2008</year>; <volume>372</volume>: <fpage>1463</fpage>–<lpage>1472</lpage>.</citation>
</ref>
<ref id="bibr53-1352458512452924">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Graham</surname><given-names>D</given-names></name>
<name><surname>Huynh</surname><given-names>NN</given-names></name>
<name><surname>Hamilton</surname><given-names>CA</given-names></name>
<etal/>
</person-group>. <article-title>Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy</article-title>. <source>Hypertension</source> <year>2009</year>; <volume>54</volume>: <fpage>322</fpage>–<lpage>328</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>